Celldex Therapeutics, Inc.
CLDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. With a market capitalization of $2.49B, it sits in mid-cap territory. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Market Cap
$2.49B
Beta
0.98
P/E (TTM)
—
P/E (Fwd)
-6.97
EPS (TTM)
$-4.27
EPS (Fwd)
$-4.55
ROE
-48.9%
ROA
-30.9%
Cash
$451.5M
Total Debt
$1.9M
Free CF
-$126.3M
52W Change
60.3%
Annual Financials
Cash vs Debt
With $451.5M in cash and $1.9M in debt, CLDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$126.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -48.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $2.4M to $1.5M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.